Completion of Medical Device Components sale

Johnson Matthey PLC
01 July 2024
 

Johnson Matthey announces completion of Medical Device Components sale

1st July 2024

 

 


Further to the announcement on 20th March 2024, Johnson Matthey Plc (JM) is pleased to announce that it has today completed the sale of its Medical Device Components business (MDC) in accordance with the terms of the sale agreement entered into between JM and Montagu Private Equity for cash consideration of US$700 million (£550 million) on a cash free debt free basis.


The board confirms its intention to return £250 million of the net proceeds from the sale of MDC by way of an on-market share buyback programme. This will commence later this week and further details will be announced in due course.


ENDS

 

 

Enquiries: 



Investor Relations

 

 

Martin Dunwoodie

Louise Curran

Director of Investor Relations and Treasury

Head of Investor Relations

+44 20 7269 8241

+44 20 7269 8235

Chris Wood

Senior Investor Relations Manager

+44 20 7269 8138

Media

 

 

Sinead Keller

Harry Cameron 

Group External Relations Director

Teneo

+44 20 7269 8218

+44 7799 152148

 

 

 

Johnson Matthey Plc is listed on the London Stock Exchange (JMAT)

Registered in England & Wales number: 00033774

Legal Entity Identifier number: 2138001AVBSD1HSC6Z10

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings